Proactive Investors - Run By Investors For Investors

Redx Pharma poster assesses the direct tumour targeting of cancer candidate

New data will be unveiled later Monday at a cancer conference in Glasgow
researcher filling a vial
A phase I/IIa trial of the porcupine inhibitor is set to resume in the first half of next year

Redx Pharma Plc (LON:REDX) will unveil a poster presentation outlining some encouraging data pointing to the direct tumour targeting effects of RXC004, its porcupine inhibitor.

The new information was garnered using colorectal and pancreatic cancer cell lines.

Redx concluded that cancer cells carrying RNF43 mutations or RSPO fusions were sensitive to RXC004 in its tests.

As such, the company believes it would be most effective as a single therapy in patients with cancers carrying those markers.

Patient screening 

This, it added, would support by a genetically-defined patient selection strategy for ongoing RXC004 clinical studies.

A phase I/IIa trial of the porcupine inhibitor is set to resume in the first half of next year in patients with what are described as “advanced malignancies”.

A poster summarising the latest data will be presented to the National Cancer Research Institute in Glasgow from noon Monday.

"We are delighted to showcase some of the fantastic science happening at Redx,” said the company’s chief medical officer, Richard Armer.

“We are encouraged by the preclinical data presented at the NCRI, which demonstrates the exquisite sensitivity of specific genetically defined cancer models to our Porcupine inhibitor, RXC004.

“The strength of these data highlight some of the broad and multiple options available for the future development of this programme as we look to re-enter the clinic in the first half of 2019."

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use